Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Holding NRIX?
Track your performance easily
NRIX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$4.96 - $27.60
Previous Close$25.43
Volume4.70M
Average Volume (3M)657.71K
Market Cap
$1.77B
Enterprise Value$1.35B
Total Cash (Recent Filing)$448.05M
Total Debt (Recent Filing)$27.14M
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Feb 12, 2025EPS Estimate
-$0.67Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.91
Shares Outstanding70,836,282
10 Day Avg. Volume1,085,037
30 Day Avg. Volume657,712
Standard Deviation0.23
R-Squared0.21
Alpha0.00160
Financial Highlights & Ratios
Price to Book (P/B)5.08
Price to Sales (P/S)31.93
Price to Cash Flow (P/CF)-10.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue23.98
Enterprise Value/Gross Profit17.57
Enterprise Value/Ebitda-8.21
Forecast
1Y Price Target
$30.50Price Target Upside12.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering13
Nurix Therapeutics News
PremiumCompany Announcements
Nurix Therapeutics Appoints Anil Kapur to BoardOwnership Overview
5.56% Insiders
17.04% Mutual Funds
4.34% Other Institutional Investors
54.86% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
NRIX FAQ
What was Nurix Therapeutics’s price range in the past 12 months?
Nurix Therapeutics lowest stock price was $4.96 and its highest was $27.60 in the past 12 months.
What is Nurix Therapeutics’s market cap?
Currently, no data Available
When is Nurix Therapeutics’s upcoming earnings report date?
Nurix Therapeutics’s upcoming earnings report date is Feb 12, 2025 which is in 94 days.
How were Nurix Therapeutics’s earnings last quarter?
Nurix Therapeutics released its earnings results on Oct 11, 2024. The company reported -$0.67 earnings per share for the quarter, beating the consensus estimate of -$0.688 by $0.018.
Is Nurix Therapeutics overvalued?
According to Wall Street analysts Nurix Therapeutics’s price is currently Undervalued.
Does Nurix Therapeutics pay dividends?
Nurix Therapeutics does not currently pay dividends.
What is Nurix Therapeutics’s EPS estimate?
Nurix Therapeutics’s EPS estimate is -$0.67.
How many shares outstanding does Nurix Therapeutics have?
Nurix Therapeutics has 70,836,280 shares outstanding.
What happened to Nurix Therapeutics’s price movement after its last earnings report?
Nurix Therapeutics reported an EPS of -$0.67 in its last earnings report, beating expectations of -$0.688. Following the earnings report the stock price went up 6.475%.
Which hedge fund is a major shareholder of Nurix Therapeutics?
Among the largest hedge funds holding Nurix Therapeutics’s share is Baker Bros Advisors LP. It holds Nurix Therapeutics’s shares valued at 81M.
---
Nurix Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.50 (12.96% Upside)
$30.50 (12.96% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.0M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 0.5%
Last 30 Days ▲ 6.6%
Last 30 Days ▲ 6.6%
Technicals
SMA
Positive
20 days / 200 days
Momentum
293.65%
12-Months-Change
Fundamentals
Return on Equity
-57.96%
Trailing 12-Months
Asset Growth
66.65%
Trailing 12-Months
Company Description
Nurix Therapeutics
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
---
NRIX Stock 12 Month Forecast
Average Price Target
$30.50
▲(12.96% Upside)
Technical Analysis
Fate Therapeutics
―
Karyopharm Therapeutics
―
Immunocore Holdings
―
RAPT Therapeutics
―
Best Analysts Covering NRIX
1 Year
1 Year Success Rate
10/14 ratings generated profit
1 Year Average Return
+69.49%
assigned a buy rating 28 days ago
Copying Gregory Renza's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +69.49% per trade.
---